PositiveID Corporation to Exhibit at the 2014 Military Health System Research Symposium Conference on August 18-21

DELRAY BEACH, Fla., Aug. 13, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today that it will exhibit at the 2014 Military Health System Research Symposium (MHSRS) Conference on August 18-21, 2014, at the Marriott Harbour Beach Resort in Fort Lauderdale, FL.

PositiveID will feature its handheld Firefly Dx system for point-of-need medical diagnostics and bio-threat detection. The Firefly Dx is designed to meet multiple military health needs with the capability to detect harmful pathogens within minutes from various sample types in a field setting.

The MHSRS is the Department of Defense's (DoD) premier scientific meeting. This Joint symposium provides a collaborative environment for military medical care providers with deployment experience, DoD scientists, academia, and industry to exchange information on research and health care advancements within the areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, and Military Infectious Disease Research Programs. It emphasizes common areas of knowledge in order to maximize synergy among all branches of the military service, while acknowledging service-specific capabilities.

This annual event provides an academic-based venue to discuss and distribute new scientific knowledge resulting from military-unique research and development. In addition, it provides a scholarly forum for planning and development of future studies aimed at optimizing care for members of the Uniformed Services in operational settings.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2014, November 19, 2013, and August 14, 2013, as amended August 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 atomek@positiveidcorp.com

Source:PositiveID Corporation